Please assess the completion status of the following clinical trial:

Trial Title: Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female previously unvaccinated healthy children aged 6 to \<36 months.~Exclusion Criteria:~* Any known or suspected impairment of the immune system, any serious disease.~* Any subjects receiving licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrollment in this study.~* Individuals who have had influenza vaccine or documented suspected influenza disease prior to day 1.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 36 Months
- Healthy Volunteers: t

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None
- Arm 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).